PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY by D. V. Blinov

“…At the same time, publications of NSP IFA pharmacoeconomic evaluation and health technology assessment in management of patients with neurological diseases are not identified. evaluation is not identified with the evaluation of publications IFA NBF in neurological disorders in terms of pharmacoeconomics and health technology assessment. …”
Get full text

S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM. by Monia Marchetti

Get full text

Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy by S. K. Zyryanov, I. N. Dyakov

“…The previously performed pharmacoeconomic study was updated considering a decrease in the cost of pembrolizumab after the generic form was released on the market and actualization of calculated target population. …”
Get full text

Comparative, Randomized, Pharmacoeconomic Evaluation of Sequential Antibiotic Therapy at the Centre Hospitalier de l’Université Laval, Sainte Foy, Quebec: A Unique Approach by MG Bergeron, AY Martel, L Bergeron, M Valois

Get full text

Clinical and Pharmacoeconomic Results of the Usage of Various HIV Reverse Transcriptase Inhibitors in the Schemes of Antiretroviral Therapy of Patients Receiving Therapy for the Chronic Hepatitis C Virus by G. F. Moshkovich, S. V. Minaeva, L. V. Varlova, M. P. Goryaeva, S. S. Gulyaeva, E. V. Tichonova

Get full text

Retraction of the article: Ryazhenov V.V., Gorokhova S.G., Bunyatyan N.D. Opportunities of the method «Budget impact analysis» for performing pharmacoeconomic research by article Editorial

Get full text

Economic evaluation of GnRH-agonist long protocol and GnRH-antagonist protocol in IVT/ICSI among the Chinese population: using pharmacoeconomic models by Min Zhang, Chunlan Chen, Junying Tang, Yuxin Si, Yalan Tang, Kexue Pu

Get full text

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER by A. U. Kulikov

“…This article presents results of comparative pharmacoeconomical estimation of this medicines in real modern health care system of Russian Federation. …”
Get full text

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer by N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov

Subjects: Get full text

Implementation of principles of pharmacoeconomics and pharmacovigilance to achieve optimal financial and therapeutic benefits through WHO - Essential medicine policy and adoption of NLEM-Based hospital formulary policy by Suresh Saravdekar, Vijay K Shukla, Omprakash P Upadhya, Madhukar Rai, Kiran Giri

Subjects: Get full text

Pharmacoeconomic advantages of using intrauterine levonorgestrel containing Mirena system in conjunction with the transdermal estrogen containing drugs for the treatment of menopausal syndrome and contraception during the menopausal transition by N G Baeva, Yu A Filyaeva

“…The current article provides the pharmacoeconomical comparison of cost-effectiveness between combined preparations for treatment of climacteric syndrome and IUD Mirena combined with trans-dermal estrogen formulations.…”
Get full text

Efficacy and pharmacoeconomic advantages of Fufang Huangbai Fluid hydropathic compress in diabetic foot infections: a comparative clinical study with antimicrobial calcium alginate wound dressing by Guangyao Yang, Guangyao Yang, Gang Wang, Zhenghong Li, Lijuan Deng, Ning Wang, Xuewan Wang, Tong Zhou, Jingming Zhang, Yin Lei, Tao Wang, Yue Wang, Hanying Shao, Mingya Chen, Keren Zhang, Min Zhou, Xiangbao Wang, Xingfang Liu, Shang Ju

Subjects: Get full text

Pharmacoeconomic analysis of Capecitabine in the adjuvant setting.... by Douillard, J, Twelves, C, McKendrick, J, Bertetto, O, Coxon, F, Diaz-Rubio, E, Dufour, P, Maughan, T, Scheithauer, W, Burris, H

Il trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici: una valutazione comparativa di costo/efficacia in una realtà psichiatrica locale by Egidio Filippelli, Giovanni Biricolti, Cinzia Scarano, Federico Russo, Lucio Luciano

Subjects: Get full text

The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults [version 2; peer revie... by Sharon Lechtig-Wassermann, Jhosep Blanco, Joshua Kock, Andrea-Marcela Suarez-Chacon, Yuli-V. Fuentes, Rosa Helena Bustos, Hans Liebisch-Rey

Subjects: Get full text

CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM by I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek

Subjects: Get full text

Analysis of assortment and volumes of consumption of antihistamin preparations in Ukraine by L.V. Iakovlieva, O. G. Berdnik, A. A. Gurtyakova

Subjects: Get full text

Economic evaluation of isosorbide mononitrate sustained-release capsules for the treatment of angina pectoris by Yuhang Liu, Jienan Zheng, Yeyou Xu, Shuli Zhang, Yueyun Li, Hui Zhang

Subjects: Get full text

Overview of Procurement and Reimbursement of Pharmaceuticals in Saudi Arabia, United Arab Emirates, Qatar, and Egypt: Challenges and Opportunities by Anas Hamad, Mai Alsaqa’aby, Yazed Alruthia, Sara Aldallal, Gihan Hamdy Elsisi

Subjects: Get full text

Health outcomes and policy in pharmay curricula among Arab countries: An evaluation of 191 academic institutions by Eman A. Alghamdi, Omar M. Albalawi, Thamir M. Alshammari

Subjects: Get full text